Peptide library
PL8177
Your guide to this compound.
Evidence in perspective
A phase 0 microdose can characterize distribution without demonstrating therapeutic efficacy. Animal colitis responses and gut restriction must not be presented as proven treatment of human inflammatory bowel disease.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Rat colitis models, animal distribution experiments and a phase 0 microdose study in healthy men.
What the sources found
Animal inflammation measures improved; human microdose work investigated distribution, not treatment efficacy.
What remains unknown
Phase 0 exposure is not evidence of efficacy in ulcerative colitis. Ordinary peptide powder is not equivalent to the studied formulation.
How it works
Targets MC1R; the polymer formulation is intended to deliver drug locally in the gut.
Targets MC1R; the polymer formulation is intended to deliver drug locally in the gut. Phase 0 exposure is not evidence of efficacy in ulcerative colitis. Ordinary peptide powder is not equivalent to the studied formulation.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- Safety details remain incomplete in this snapshot; absence of a listed effect does not mean it was excluded.
Contraindications
- This snapshot is not a complete contraindication or interaction review.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
References
Primary publication · PMID 36891301
PMID: 36891301
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.